AT-1015 is a novel selective 5-HT 2A serotonin receptor antagonist that is known to impair platelet aggregation and vasoconstriction. Serotonin has been hypothesized to contribute to claudication symptoms in individuals with peripheral arterial disease (PAD) via microvascular vasoconstrictor and thrombotic effects. AT-1015 was thus evaluated in 439 patients with claudication who were randomized in a double-blind, placebo-controlled trial comparing 10 mg, 20 mg, and 40 mg BID versus placebo for 24 weeks. Treadmill walking performance was assessed by peak walking time (PWT) and pain-free walking time (PFWT). Quality of life (QoL) was measured by the Walking Impairment Questionnaire (WIQ) and the Health Status Survey SF-36. Limb hemodynamics was assessed with the ankle¡brachial index (ABI). The 40 mg arm was terminated prematurely by recommendation of the Data Safety Monitoring Committee due to an excess number of non-fatal myocardial infarctions. At study conclusion, there were no statistically signi cant differences in the mean change of PWT, PFWT, ABI and QoL between the 10 mg and 20 mg BID treatment groups compared with placebo. The proportion of patients who experienced an adverse event (AE) was similar across all treatment groups. Antimuscarinic and gastrointestinal AEs were more common in the AT-1015 treatment groups. Two deaths occurred: one in the placebo group and the other in the AT-1015 20 mg group. Although a prolongation of the QTc interval was observed in all groups, this was not clinically signi cant (QTc > 500 ms). Mean supine pulse rates were signi cantly increased in all AT-1015 treatment groups, consistent with predicted antimuscarinic effects. Population pharmacokinetic analysis t a one-compartment model with rst-order absorption and elimination. These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication.
Introduction
Intermittent claudication is the most common symptom of peripheral arterial disease (PAD ), affecting 30¡40% of this patient population. 1¡3 Claudication is associated with a reduced functional capacity that limits the ability of patients to perform activities of daily living. 4 Treatment of claudication focuses on relief of leg symptoms that occur with exertion and improvement in both walking capacity and quality of life. Pharmacologic treatment of claudication is currently limited to only two approved medications in the USA, 5 pentoxifylline and cilostazol. Pentoxifylline has long been available, but its ef cacy is considered uncertain. 6 Cilostazol, a phosphodiesterase type 3 inhibitor, improves treadmill walking distance and quality of life in a high fraction of treated patients. 7 However, use of cilostazol can sometimes be limited by adverse effects (headache, palpitations, gastrointestinal discomfort, or diarrhoea) and is contraindicated for patients with heart failure. As well, the maximal response to currently available claudication medications is not always adequate to satisfactorily improve quality of life.
Although the pathophysiology of claudication is multifactorial, drugs that modulate vascular tone via increases in cAMP levels in vascular smooth muscle and by decreasing platelet aggregation (such as cilostazol) have shown clinical ef cacy. 8 5-Hydroxytryptamine (5-HT or serotonin) is a neurotransmitter essential for a large number of physiological processes, and also is known to contribute to the regulation of vascular and nonvascular smooth muscle contraction, modulation of platelet aggregation, and several functions of the central nervous system. 9, 10 Ketanserin, a selective 5-HT 2 serotonin antagonist, was found to be effective for the treatment of intermittent claudication in several clinical trials, suggesting that endogenous levels of vascular 5-HT may contribute to the pathophysiology of intermittent claudication. 11 H owever, although ef cacy was demonstrated, the Prevention of Atherosclerotic Complications with K etanserin (PACK) trial also raised several safety concerns. F or example, ketanserin prolonged the corrected QT interval and was thought to be potentially harmful when combined with potassium wasting diuretics. 12 N ewer drugs in this class include AT-1015 (Ajinomoto Pharmaceuticals U SA, Inc., Paramus, NJ, USA), a novel selective 5-HT 2A serotonin receptor antagonist that was developed for the treatment of intermittent claudication. AT-1015 blocks 5-HTinduced platelet aggregation and vasoconstriction. 13 AT-1015 was shown to be safe in a comprehensive series of Phase I and II trials, without associated prolongation of the QT interval, over a relevant dose¡response range (Ajinomoto database on le).
Based on these initial ndings, the current study was designed to evaluate the safety and ef cacy of AT-1015 in a larger population of patients with intermittent claudication. Population pharmacokinetics was also assessed. Doses selected in the present study were derived from previous studies demonstrating their relative safety and tolerability. We hypothesized that AT-1015 would increase peak walking time compared with placebo in patients with claudication.
Methods
The study was designed in accordance with the recommendations of the Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease. 14 The study was conducted with Institutional Review Board approval. Written informed consent was obtained from each participant prior to study enrollment.
Patient population
Eligible patients had PAD con rmed by a resting ankle¡ brachial index (ABI) 0.90 with a 10% decrease postexercise. These patients also had stable symptoms ( 6 months) of intermittent claudication, as de ned as exertional calf pain relieved by rest. Claudication had to be the limiting symptom during treadmill exercise. Patients were excluded from participation if they had undergone limb arterial bypass surgery, angioplasty, or lumbar sympathectomy within the past 6 months. Other exclusion criteria were a history of cerebral, subarachnoid, or subdural haemorrhage; clinically signi cant vascular aneurysm; severe hypertension; serious cardiac conditions (such as congestive heart failure) or a limiting pulmonary condition (such as chronic obstructive pulmonary disease). Other exclusion criteria included severe concomitant diseases (renal, hepatic, or oncologic); uncontrolled diabetes (glycohemoglobin > 11%) or diabetic neuropathy or gastroparesis; substance abuse; or treatment with a drug likely to induce toxicity in a major organ system within 3 months of enrollment. Finally, patients were excluded for myocardial infarction, unstable angina, or coronary angioplasty within 6 months prior to enrollment. D rugs with potential bene t for treating claudication and thereby confounding the results (pentoxifylline, cilostazol, ginko biloba, L-arginine, or L-carnitine) were prohibited during the study. Because AT-1015 has antiplatelet effects, anticoagulants (except warfarin), combination therapy with two antiplatelet agents, such as aspirin plus clopidogrel, or concomitant warfarin and clopidogrel were also excluded in order to reduce the risk of bleeding. Drugs which could interfere with the metabolism of AT-1015, or medications that alter cytochrome P450 3A4 metabolism ( uconazole, itraconazole, ketoconazole, or miconazole; anti-HIV protease inhibitors; and grapefruit juice) were excluded from the trial. Other concomitant medication doses, diet, and exercise regimens were to remain constant throughout the course of the study.
Study design
This was a multicenter, randomized, double-blind, placebo-controlled, parallel group study of patients with intermittent claudication due to PAD comparing AT-1015 at 10 mg, 20 mg, and 40 mg doses versus placebo administered twice a day for 24 weeks. Study medication was given after breakfast and after the evening meal. A total of 439 patients were enrolled at 47 study centers in the U SA.
F our weeks before study initiation, patients underwent a screening evaluation, which included a graded treadmill test (described below). Two baseline treadmill tests (separated by a week) were performed to measure the peak walking time (PWT) and pain-free walking time (PF WT). If the PWT values on both baseline tests were between 1 and 12 min and if the variation between PWT values was 25%, patients were randomized to double-blind study medication at the second baseline visit. An additional treadmill test, approximately 1 week later, was offered to those patients who failed to meet the PWT criteria at the second baseline visit. Patients meeting PWT entry criteria at the third visit were randomized to treatment at that visit. Treadmill walking performance (assessed by PWT and PF WT) was evaluated after randomization at weeks 12, 23, and 24.
F unctional status was measured by the disease-speci c Walking Impairment Questionnaire (WIQ), which evaluates patient-reported walking speed, distance, stair-climbing ability, and limitations in walking ability due to speci c symptoms. Subjects also were evaluated by the Health Status Survey SF -36 questionnaire (SF -36), which includes assessments of physical, social and role functioning in daily life, general health and well-being, and satisfaction with treatment, at the rst baseline visit and at weeks 12 and 24. Limb hemodynamics were assessed with a resting ABI measured prior to each treadmill test.
Speci c methods
Treadmill testing was performed using a graded treadmill with a constant speed of 2 miles per hour (3.2 km=h) and a grade that began at 0% and increased 3.5% every 3 min. 15 At the end of each stage, heart rate, blood pressure and an electrocardiogram (ECG ) recording were obtained. The baseline tests were considered valid only if claudication V ascular M edicine 2004; 9: 18-25 symptoms caused the patient to stop walking. Walking performance measurements during the double-blind treatment phase were considered valid even if terminated for reasons other than symptoms of claudication. The primary measure of ef cacy was the change in the PWT from baseline to the end of the study. Secondary measures were changes from baseline to endpoint in PF WT, ABI at rest, and the two functional status questionnaires (WIQ and SF -36). Safety was assessed by adverse event reports and ndings on physical examinations (including measurements of blood pressure and pulse rate), clinical laboratory tests, and ECG at rest and during the exercise test.
The ABI was obtained with a continuous wave Doppler ultrasonic instrument to detect the arterial pulse and to measure systolic pressures at the dorsalis pedis and posterior tibial arteries in each ankle and in the brachial artery in each arm. The right and left ABI values were then calculated from the vessel at each ankle with the highest pressure divided by the single highest arm pressure. The index leg was de ned as the leg with the lowest ABI and was used for all subsequent ABI measurements. F unctional status was assessed by the WIQ and the SF -36. 16 The population pharmacokinetics of AT-1015 was evaluated by analysing the plasma concentration of the agent by liquid chromatography with a lower limit of quantitation of 0.100 ng=ml (sponsor data). Pre-dose specimens were obtained before study medication was administered, trough specimens were obtained prior to administration of study medication at prespeci ed study visits, and post-dose specimens were obtained at various prespeci ed time points after administration of study medication (ranging from 1 to 2 and 6 to 8 h post dose) to optimize the evaluation of concentration measurements at peak and trough times.
Changes in study conduct and planned analyses
During the conduct of the study, the Chairman of the Drug Safety Monitoring Committee (DSM C) (see 'Acknowledgements') informed the Steering Committee and the study sponsor of its recommendation that the AT-1015 40 mg arm should be terminated because of an excess of serious cardiovascular adverse events observed in that treatment group. All study centers were informed of this decision and were instructed to immediately withdraw all patients in the AT-1015 40 mg group from treatment. No concern was expressed regarding other treatment groups, and conduct of the study continued as planned.
Statistical analysis
The ef cacy population included all patients who received at least one dose of double-blind study medication and had a baseline and at least one post-treatment value for any ef cacy variable. The primary ef cacy assessment was change in PWT from baseline (mean of last two qualifying treadmill test values) to endpoint (mean of week 23 and week 24 values). The last observation carried forward (LOCF ) method was used to determine missing endpoint values. A similar analysis was performed for the secondary ef cacy variable of PF WT.
Statistical hypothesis tests were two-sided and were considered to be signi cant if the p-value was 0.05. For the primary ef cacy analysis of change in PWT from baseline to endpoint, Dunnett's multiple comparison procedure was employed using log-transformed data. The three active treatment groups were compared with the placebo group using an analysis of covariance (AN COVA) model including effects for treatment, center, and mean baseline PWT. The analysis of change in PF WT from baseline to endpoint was performed in a manner similar to the PWT analysis.
The impact of early termination of the 40 mg dosing arm on ef cacy was further explored by rerunning analyses of PWT and PF WT after excluding data collected after the date of the last on-study treadmill test for patients in the 40 mg arm. These truncated analyses provided a useful approach to assessing the dose¡response relationship among active dosing arms without any potential biases introduced due to the early termination of the 40 mg arm. Analyses of the change in PWT from baseline to LOCF endpoint were also performed for subgroups stratied by age, sex, race, presence of diabetes, smoking status, baseline PWT, baseline resting ABI, concomitant aspirin, and concomitant use of clopidogrel.
Changes in resting ABI at week 24 and the WIQ and SF -36 scores were analysed using an ANCOVA model with terms for baseline as a continuous variable and center and dose as nominal variables.
The safety population consisted of all patients who received at least one dose of double-blind study medication. The overall incidence of adverse events in each AT-1015 dose group was compared with placebo using a two-tailed F isher's exact test. The distribution of severity of adverse events was compared using the Mantel¡ Haenszel chi-squared statistic with rank scores. Vital signs (systolic and diastolic blood pressure and pulse rate) and quantitative ECG variables (PR interval, QRS interval, QTc interval) were summarized descriptively by treatment group. In addition, changes from baseline in supine and standing pulse rate and QTc interval were analysed using an AN COVA model with terms for baseline as a continuous variable and center and dose as nominal variables. QTc was calculated according to Bazett's formula, as well as the correction methods of F ridericia and F ramingham, 17 which are not as susceptible to heart rate increases.
The sample size of 80 patients per group was selected to provide 80% power to detect a 105 s difference in the primary ef cacy endpoint of change from baseline to study end in PWT between each AT-1015 dose group and placebo. In order to maintain an experiment-wide, two-sided aˆ0.05, Dunnett's multiple comparison method was employed and a standard deviation of 200 s was assumed for the change in PWT. A similar power analysis using a log scale transformation of PWT scores resulted in similar sample size requirements.
Results

Patient disposition and demographic data
A total of 823 patients with intermittent claudication were screened for study participation, of whom 439 conformed to all entry criteria and were randomized to treatment, and 434 received at least one dose of study medication (F igure 1). The number of patients who discontinued treatment early was similar in the placebo and the AT-1015 10 mg and 20 mg treatment groups. In the AT-1015 40 mg group, 67 patients discontinued treatment prematurely, of which 39 discontinued as a result of the recommendation by DSMC to terminate this study group. Because the AT-1015 40 mg arm of the study was terminated early, the mean number of days of exposure to study medication differed, with patients in the 40 mg group having 98 days versus 151¡153 days in the other treatment groups.
D emographic characteristics and baseline measurements for all patients who received 1 dose of study medication, including all patients enrolled in the AT-1015 40 mg group, are shown in Table 1 . The treatment groups were well balanced with respect to sex, age, race, height, and weight; the proportion of patients with diabetes and smokers were uniform across treatment groups. Mean baseline PWT was 4.6 2.6 min and mean PF WT was 2.5 1.5 min.
Ef cacy
Peak walking time
No statistically signi cant differences were observed among treatment groups in the primary ef cacy endpoint of the mean change in PWT from baseline to LOCF Figure 1 Number of patients screened, randomized to treatment, received study medication, terminated the study prematurely, and completed the study. endpoint (analysed using log transformed data to correct for non-normal distribution). The raw mean change scores and the mean per cent changes (back transformed from the log transformed data used for the analysis) for all groups for the endpoint analysis are shown in F igures 2 and 3, respectively. Exploratory analyses of the mean change in PWT from baseline to endpoint in subgroups de ned by age, sex, race, diabetes, smoking status, baseline PWT, baseline resting ABI, and concomitant aspirin or clopidogrel revealed no subgroup differences. Similarly, a comparison of the proportion of patients with an increase in PWT 50% or 30% of the baseline value revealed no differences across treatment groups (F igure 4).
S econdary endpoints
There were no statistically signi cant differences for any of the secondary ef cacy measures, including PF WT, ABI, and QoL measures (WIQ, SF -36). A 'truncated' analysis of PWT ef cacy data available at the time of termination of the AT-1015 40 mg group also yielded similar results to the main analysis.
Adverse events
Overall adverse events pro le The overall AE pro le for the safety population (all patients who received 1 dose of study medication) is summarized in Table 2 . The proportion of patients experiencing an AE was similar among those randomized to treatment with AT-1015 compared with those receiving placebo. The most common AEs in the AT-1015 treatment groups were gastrointestinal, which were statistically more prevalent in the active treatment groups than in the placebo group (16 patients on placebo versus 31, 41 and 44 patients receiving AT-1015 10 mg, 20 mg, and 40 mg, respectively [p < 0.05, F isher's exact test]). The proportion of patients discontinuing treatment prematurely because of an AE was signi cantly higher in the AT-1014 10 mg and 40 mg groups than in the placebo group (p 0.05, F isher's exact test). As anticipated, antimuscarinic AEs were more common among patients receiving AT-1015 than among those receiving placebo (Table 3 ). Constipation and dry mouth were signi cantly more prevalent among patients in the AT-1015 20 mg and 40 mg groups than among those in the placebo group (p 0.05, Fisher's exact test).
S erious cardiovascular events ( S AEs) and deaths
Although the number of patients experiencing cardiovascular SAEs was similar in the active treatment and placebo groups, all ve patients who experienced a myocardial infarction (M I) were in the AT-1015 groups: one in the 10 mg group and four in the 40 mg group ( Table 2) . The proportion of patients experiencing a M I (nˆ4) while on treatment was signi cantly higher in the AT-1015 40 mg group than in the placebo group (p 0.05, F isher's exact test). F or this reason the DSM C stopped that study arm. Two deaths occurred during treatment attributed to cardiac arrest: one in the placebo group and one in the AT-1015 20 mg group.
Electrocardiographic and pulse rate changes
A prolongation of the QTc interval was noted in all active treatment and placebo groups, although few patients had a prolongation of the QTc > 500 ms. When Bazett's correction method was applied to the QTc values, there was a statistically signi cant (pˆ0.007) increase from baseline in the mean QTc interval in the AT-1015 40 mg group compared with the mean change in the placebo group at weeks 8, 16, and 20. At week 20, a 30¡60 ms increase in QTc was noted in 9=36 (25%) and 9=90 (10%) patients in the AT-1015 40 mg and placebo groups, respectively. However, when alternate correction methods, such as the F ridericia and F ramingham methods, were applied, significant increases in QTc prolongation were not found. Consistent with previously observed anti-muscarinic side effects, mean supine pulse rates increased signi cantly in all AT-1015 treatment groups versus placebo (3.4, 4.1 and 4.6 beats=min for the AT-1015 10 mg, 20 mg, and 40 mg groups, respectively; p < 0.05).
Population pharmacokinetics
Population pharmacokinetic analysis indicated that a one-compartment model with rst-order absorption and elimination adequately described the individual plasma concentration-time data for AT-1015. The population values for oral clearance (CL=F ) and apparent volume of distribution (V=F ) were estimated to be 140 l=h and 2140 l, respectively. The estimated AT-1015 half-life was 10 h, a value consistent with results from the Phase I studies.
Inter-individual variability on both CL=F and V=F ranged from 27.6% to 36.1%.
The population analysis examined the effect of demographic characteristics (age, gender, body weight, and race), of laboratory values re ecting hepatic and renal function, of comorbid disease states, and of concomitant medications on AT-1015 pharmacokinetics. Of these variables, only gender, body weight, and concomitant use of other medications that inhibit CYP3A4 were identi ed as factors that in uenced AT-1015 pharmacokinetics.
Gender and CYP3A4 inhibitors in uenced CL=F, whereas body weight in uenced V=F . The median values for CL=F in female and male patients were 113 l=h and 140 l=h, respectively. Concomitant use of medications that inhibited CYP3A4 decreased median values of CL=F in female and male patients to 73 l=h and 90 l=h, respectively. These data notwithstanding, these two variables still only accounted for 6% of the variability in CL=F , indicating that a host of other unidenti ed factors in uence the elimination of AT-1015. The V=F of AT-1015 was found to increase with increasing body weight; the median estimate for a typical patient with a body weight of 80 kg was 2140 l. V=F increased by 37% over the body weight range of 47.7¡138.6 kg. As observed with CL=F , this variable only accounted for a small fraction of the overall variability in V=F (9%), meaning that a number of other factors also contribute to the volume of distribution in an individual patient.
Discussion
Serotonin (5-HT) is a vasoactive compound that is stored in dense granules within the platelet and is believed to be an important mediator of vasospasm associated with atherosclerosis. Serotonin is also presumed to be pathophysiologically linked to various disease states such as hypertension, peripheral arterial disease, and coronary spasm. 5-HT receptors are divided into 5-HT 1 and 5-HT 2 , which have been further categorized into subtypes such as 5-HT 2A and 5-H T 1 -like receptor subtypes, responsible for vasoconstriction. 18 Hence, AT-1015, a potent 5-HT 2A receptor antagonist, was thought to be potentially effective for the treatment of claudication due to peripheral arterial disease.
The results of the present study did not support the hypothesis that AT-1015 would improve treadmill performance in patients with claudication. Importantly, the study was suf ciently powered to detect differences in efcacy among treatment groups, even after the early termination of the highest dose of AT-1015 (40 mg). The analyses of primary and secondary ef cacy parameters also did not demonstrate differences between any active treatment groups of AT-1015 when compared with placebo (PF WT and the questionnaire results). The study was appropriately designed and executed in that it was randomized and blinded and enrolled subjects with similar baseline demographic characteristics across treatment groups. Moreover, the comparability of plasma concentrations of AT-1015 across the tested dosing range with those in previous studies (Ajinomoto database on le) also adds a measure of con dence in the results.
An excess number of M Is in the 40 mg study arm led the DSMC to recommend termination of this AT-1015 dose. Exploration of the potential causal relationship of AT-1015 to these events did not discern a speci c unifying etiologic mechanism. The effects of 40 mg AT-1015 on the QTc interval, blood pressure, or heart rate were relatively small and were not considered to be clinically meaningful (data not shown). As the treatment groups were inadequately powered to detect infrequent events, such as MI, it was not possible to determine the true frequency and causality of these serious cardiovascular events.
This study demonstrated a dose¡response relationship for adverse effects and overall tolerability. The 10 and 20 mg doses were well tolerated whereas the 40 mg dose was not, as evidenced by a 26% discontinuation rate in the latter group due to adverse events. The most common adverse events were constipation, dry mouth and urinary retention, which are consistent with the antimuscarinic activity of AT-1015 observed in previous studies. F uture studies with AT-1015 would need to recognize that the drug is metabolized via the cytochrome P450 3A4 pathway. Thus, other drugs (e.g. ketoconazole) undergoing similar metabolism could potentially interfere with its clearance and lead to accumulation of AT-1015. H ence, concomitant use of inhibitors of the 3A4 pathway would need to be excluded in future clinical trials.
In conclusion, AT-1015 was found to be ineffective in improving exercise tolerance or quality of life in patients with intermittent claudication. Given the negative results of this study, the pharmacologic blockade of selective serotonergic receptors may not be a useful approach to the treatment of claudication. F urther, activation of the serotonin receptor pathways may not be central to the pathogenesis of the symptom of claudication and the limited exercise performance experienced by these patients with established vascular disease. Additional studies would be needed to evaluate any potential role of AT-1015, or other serotonin receptor antagonists, in treating the symptoms of PAD , or the utility of this class of drugs at earlier stages of the disease.
